[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":97},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100573526","high-fat-diet-for-cardiac-metabolic-reprogramming-100573526",false,"NCT06747429","High Fat Diet for Cardiac Metabolic Reprogramming","Cardiac Metabolic Reprogramming by a Nutritional Intervention: the High Fat Diet for Heart Failure (HF4HF) Study, a proof-of Concept Randomized Controlled Trial","HF4HF","Inclusion Criteria:\n\n* Patients of both sexes and ≥18 years old\n* Patients diagnosed with HF secondary to non-ischemic DCM, according to ESC guidelines definition,1 with or without a known genetic basis.\n* LVEF ≤49% according to the baseline CMR.\n* Optimized HF guideline-directed medical therapy for at least 3 months prior to inclusion.\n* Patients who have provided informed consent.\n\nExclusion Criteria:\n\n* Prior diagnosis of ischemic DCM.\n* Prior diagnosis of established atherosclerotic cardiovascular disease (angina\u002Fmyocardial infarction, transient ischemic attack\u002Fstroke, lower limb ischemia or at any other peripheral level).\n* Changes in HF therapies within the last 3 months.\n* HF decompensation within the previous 3 months, including HF hospitalization or the need of ambulatory intravenous diuretic or inotropic treatment such as levosimendan.\n* Uncontrolled dyslipidemia, defined as LDL-cholesterol \\>160 mg\u002FdL and\u002For triglycerides \\>200 mg\u002FdL, despite treatment.\n* Any contraindication for CMR:\n\nSevere claustrophobia. Any device which is known to threaten or pose hazard in all MR environments. \u002F\u002Fwww.mrisafety.com\u002F Patients with implanted biomedical devices (cardiac artefacts): pacemakers, cardiac defibrillators or cardiac resynchronization therapy.\n\n* Liver and biliary diseases, including prior diagnosis of non-alcoholic fatty liver disease and unoperated cholelithiasis.\n* Prior episodes of acute pancreatitis or chronic pancreatitis.\n* Prior fish or nut allergy.\n* Life expectancy less than 12 months.\n* Pregnancy or planned pregnancy for the next 4 months.\n* Current lactation.\n* Patients participating in other randomized clinical trial.\n* Impossibility to consent or undergo study follow-up","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","Heart failure (HF) continues to be a leading cause of morbidity and mortality worldwide, despite advances in treatment. HF is often characterized by an altered metabolism in the heart, where glucose is favored over fatty acids as the primary energy substrate. This metabolic shift has been hypothesized to contribute to disease progression. Previous studies using animal models have demonstrated that restoring fatty acid metabolism through dietary intervention can reverse the adverse metabolic effects and improve heart function. A transgenic murine model with mitochondrial defects, for instance, exhibited improved cardiac function after an HFD intervention. These findings were reinforced by a translational pig model of non-ischemic DCM, where a high-fat diet significantly improved LVEF compared to a standard diet.\n\nBuilding upon these promising preclinical results, a small-scale human study showed that lipid infusion, rather than glucose, improved cardiac function in HF patients. However, the long-term benefits of a HFD in heart failure patients have yet to be thoroughly explored. The HF4HF trial aims to fill this gap by evaluating the effects of an HFD over a two-month period in patients with non-ischemic DCM and reduced LVEF.\n\nThe \"High Fat Diet for Heart Failure\" (HF4HF) study is a proof-of-concept randomized controlled trial designed to investigate the efficacy of a high-fat diet (HFD) as a therapeutic intervention in patients with non-ischemic dilated cardiomyopathy (DCM) and reduced left ventricular ejection fraction (LVEF). The study hypothesizes that cardiac metabolic reprogramming, achieved through a controlled nutritional intervention involving an HFD, can enhance systolic function, myocardial energetics, and overall heart function in heart failure (HF) patients. Cofunded by the European Commission and national entities, the trial is spearheaded by a consortium of cardiovascular research centers across four countries: Spain, Italy, France, and Romania.",[27,28],"Non-ischemic Dilated Cardiomyopathy","Heart Failure With Reduced Ejection Fraction",[30,31,32,33],"heart failure","high-fat diet","clinical trial","non-ischemic DCM","RECRUITING","2026-05-21",{"date":37,"type":38},"2026-05-26","ACTUAL",{"date":40,"type":38},"2026-01-15",{"date":42,"type":21},"2026-12",{"name":44,"class":45},"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","OTHER",5,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100568871","phase-3-non-steroidal-anti-inflammatory-drugs-in-acute-myocarditis-100568871","NCT06686862","Non-Steroidal Anti-Inflammatory Drugs in Acute Myocarditis","Non-Steroidal Anti-Inflammatory Drugs Versus Conventional Treatment in Acute Myocarditis (INFLAMA Trial)","INFLAMA","Inclusion Criteria:\n\n* Aged 18 years or older.\n* Patients hospitalized for confirmed acute myocarditis and left ventricular ejection fraction ventricular \\>50%.\n* Elevated troponin I\u002FT (3 times above the upper limit of normal).\n* Absence of acute heart failure.\n* Absence of ischemic heart disease (ruled out by coronary angiography or coronary CT in individuals over 40 years).\n* Diagnostic criteria for myocarditis (Lake Louise, 2018 update) by cardiac magnetic resonance imaging.\n\nExclusion Criteria:\n\n* Kidney disease stage 3b, 4 and 5 (creatinine clearance by CKD-EPI \\\u003C45 ml\u002Fmin\u002F1.73 m2).\n* Severe liver failure (Child-Pugh class C).\n* Poorly controlled pharmacological hypertension (repeatedly systolic arterial pressure \\>140 mmHg).\n* Diagnosis criteria for acute pericarditis.\n* Moderate or severe pericardial effusion (\\>10 mm in total).\n* Hypersensitivity to NSAIDs or previous use in the last 7 days.\n* Contraindication for MRI.\n* Participation in another clinical trial.\n* Pregnancy, breastfeeding, or women of childbearing age unwilling to use appropriate contraception throughout the study.\n* Any circumstance that, in the investigator's opinion, compromises participation in the clinical trial.",{"count":56,"type":21},150,[58],"PHASE3","Prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of a 3-week ibuprofen tapering regimen compared to conventional analgesic treatment (acetaminophen) in patients with acute myocarditis and left ventricular ejection fraction ≥50%. The objective is to assess the reduction in late gadolinium enhancement on cardiac magnetic resonance imaging at 6-month follow-up.",[61],"Myocarditis Acute",[63,64],"Nonsteroidal antiinflammatory agents","Magnetic Resonance Imaging","2026-02-12",{"date":67,"type":38},"2026-02-13",{"date":69,"type":38},"2025-04-28",{"date":71,"type":21},"2027-10",{"name":44,"class":45},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":95,"locationsCount":96},"100456424","remote-ischemic-conditioning-in-lymphoma-patients-receiving-anthracyclines-100456424","NCT05223413","REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs","RESILIENCE","Inclusion Criteria:\n\n≥18 years old NHL, HL or breast cancer diagnosis Scheduled to undergo chemotherapy including ≥ 240 mg\u002Fk2 cumulative dose of anthracyclines.\n\nPre-chemo LVEF \\>40% on screening echocardiography.\n\nPresence of ≥1 of the following risk factors for developing cardiotoxicity:\n\nPrevious coronary artery disease (any of the following):\n\nPrevious coronary revascularisation (PCI or CABG) or Medical history of previous significant nonrevascularized coronary stenosis Previous Acute Coronary Syndrome \u002F Acute Myocardial Infarction with a LVEF \\> 40 LVEF 41-54% Age ≥ 65 years old Previous diagnosis of arterial hypertension (with or without treatment) Chronic kidney disease (estimated glomerular filtration rate \\\u003C60ml\u002Fmin\u002F1.73m2) Current or former smoker. Obesity (BMI≥30 kg\u002Fm2) LVH on screening echocardiography (LV thickness ≥12mm). High alcohol intake (≥21 alcoholic beverages per week) Sinus rhythm on screening ECG Previous diagnosis of diabetes (except those treated with sulfonylureas or those with neuropathy) Previous non-anthracycline-based chemotherapy Signed Informed Consent Form (ICF)\n\nExclusion Criteria:\n\n* History of any of the following diseases:\n\n  * Any cancer who received anthracyclines treatment before the index episode.\n  * Previous clinical diagnosis of heart failure.\n  * Permanent atrial fibrillation (AF).\n  * Severe valvular or sub-valvular heart disease.\n  * Severe peripheral arterial disease in the upper extremities or arteriovenous (AV) shunt in the arm selected for RIPC.\n* Clinical diagnosis of diabetes neuropathy\n* Contraindication for CMR:\n\n  * Severe claustrophobia.\n  * Any device which is known to threaten or pose hazard in all MR environments (http:\u002F\u002Fwww.mrisafety.com\u002F).\n  * Patients with implanted biomedical cardiac devices: pacemakers, ICDs or CRT.\n* Severe thrombocytopenia (platelets \\\u003C50,000\u002FµL) on any blood test within the previous 3 months.\n* Patients participating in other clinical trials.\n* Impossibility to consent or undergo study follow-ups.","99 Years",{"count":83,"type":21},608,[24],"Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning (RIPC) in Lymphoma patients receiving anthracyclines.",[87,88],"Anthracycline-induced Cardiac Toxicity","Lymphoma","2025-09-12",{"date":91,"type":38},"2025-09-18",{"date":93,"type":38},"2022-01-18",{"date":42,"type":21},{"name":44,"class":45},24,""]